Northbank named as PR agency for IntegraGen

Northbank Communications is pleased to announce that it has been appointed as PR and communications consultants to IntegraGen, a personalised medicines company, based in France. Northbank will provide communications support for a range of activities, encompassing media outreach and investor relations.

IntegraGen is based in the Evry Genopole, a scientific hub focused solely on genetic research and the development of biotechnology companies. Using its unique genome analysis technology, GenomeHIP^®, the company identifies genes associated with complex and high profile diseases such as obesity, type 2 diabetes, and specific neurological diseases like autism and bipolar disorder. GenomeHIP represents the next generation in gene discovery technology, overcoming many of the disadvantages of the slower more traditional approaches. The validated gene targets discovered will be used in the development of novel molecular diagnostics in-house and new drugs in partnership with other companies.

Northbank has already worked with IntegraGen to develop a package of materials for inclusion in the publication Business Briefings, including a corporate advertisement and a technical review article, and has announced IntegraGen’s new collaborative deal with Aventis to use its GenomeHIP technology to identify genes associated with schizophrenia.

Sue Charles, CEO of Northbank, said “We are very please to be working with IntegraGen. As the company is based in Paris it will facilitate our expansion into the French market.”

The account will be led by Sue Charles, with account management provided by Dr Rebecca Todd.

back to news

© 2007 College Hill Associates | Registered in England No 1036926 / VAT No 245666930 | Legal